SRR25617937
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.430
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V1+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.180
- MITOTIC_SPINDLE+0.170
- SPERMATOGENESIS+0.150
- DNA_REPAIR+0.140
- OXIDATIVE_PHOSPHORYLATION+0.120
- MTORC1_SIGNALING+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- ESTROGEN_RESPONSE_EARLY-0.340
- ALLOGRAFT_REJECTION-0.310
- APOPTOSIS-0.290
- P53_PATHWAY-0.290
- ESTROGEN_RESPONSE_LATE-0.280
- MYOGENESIS-0.280
- ANGIOGENESIS-0.260
- BILE_ACID_METABOLISM-0.260
- INTERFERON_ALPHA_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650205 | — | — | 0.925 |
| 2 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.925 |
| 3 | MNG704 | — | — | 0.916 |
| 4 | SRR13780247 | — | cohortMD1 | 0.912 |
| 5 | BS_YETBN0RQ | medulloblastoma | — | 0.910 |
| 6 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.905 |
| 7 | BS_N6N147BY | Embryonal tumors | — | 0.903 |
| 8 | BS_1HQ76V6D | Embryonal tumors | — | 0.902 |
| 9 | 20120209.TNBC | — | E | 0.896 |
| 10 | BS_TZVFR600 | medulloblastoma | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |